Develop and register acoziborole as a new, single-dose, oral treatment for T.b. gambiense sleeping sickness
current phase of drug development
updated 1 Jun 2021
In late 2009, acoziborole was selected as a pre-clinical candidate to treat sleeping sickness caused by T.b. gambiense. DNDi’s own lead optimization project led to the selection, starting with an initial hit identified in the Anacor chemical library. In 2012, acoziborole became the first new chemical entity to enter clinical development from DNDi’s own lead optimization programme.
The delivery of fexinidazole, a new all-oral treatment for Stage 1 and Stage 2 sleeping sickness, greatly improved therapeutic options for the disease. But the development of an additional oral drug, especially one that could be given as a one-day, single-dose treatment, could simplify administration and strengthen efforts towards sustained elimination of the disease.
News and publications
Get our latest news, personal stories, research articles, and job opportunities.